562 related articles for article (PubMed ID: 30605011)
1. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
[TBL] [Abstract][Full Text] [Related]
2. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway.
Yusta B; Matthews D; Flock GB; Ussher JR; Lavoie B; Mawe GM; Drucker DJ
Mol Metab; 2017 Jun; 6(6):503-511. PubMed ID: 28580281
[TBL] [Abstract][Full Text] [Related]
4. OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.
Ma SY; Ning MM; Zou QA; Feng Y; Ye YL; Shen JH; Leng Y
Acta Pharmacol Sin; 2016 Sep; 37(10):1359-1369. PubMed ID: 27264313
[TBL] [Abstract][Full Text] [Related]
5. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
6. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.
Zhou D; Chen YW; Zhao ZH; Yang RX; Xin FZ; Liu XL; Pan Q; Zhou H; Fan JG
Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30510243
[TBL] [Abstract][Full Text] [Related]
7. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.
Huang S; Ma S; Ning M; Yang W; Ye Y; Zhang L; Shen J; Leng Y
Metabolism; 2019 Oct; 99():45-56. PubMed ID: 31295453
[TBL] [Abstract][Full Text] [Related]
8. The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.
Ookawara M; Matsuda K; Watanabe M; Moritoh Y
J Pharmacol Exp Ther; 2020 Oct; 375(1):21-27. PubMed ID: 32719069
[TBL] [Abstract][Full Text] [Related]
9. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
10. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice.
Briere DA; Ruan X; Cheng CC; Siesky AM; Fitch TE; Dominguez C; Sanfeliciano SG; Montero C; Suen CS; Xu Y; Coskun T; Michael MD
PLoS One; 2015; 10(8):e0136873. PubMed ID: 26312995
[TBL] [Abstract][Full Text] [Related]
11. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
[TBL] [Abstract][Full Text] [Related]
12. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
[TBL] [Abstract][Full Text] [Related]
13. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.
Bahirat UA; Shenoy RR; Talwar R; Goel RN; Nemmani KVS
Biochem Biophys Res Commun; 2018 Jan; 495(2):1608-1613. PubMed ID: 29203247
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
16. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
17. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M
J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823
[TBL] [Abstract][Full Text] [Related]
18. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.
Baumeier C; Schlüter L; Saussenthaler S; Laeger T; Rödiger M; Alaze SA; Fritsche L; Häring HU; Stefan N; Fritsche A; Schwenk RW; Schürmann A
Mol Metab; 2017 Oct; 6(10):1254-1263. PubMed ID: 29031724
[TBL] [Abstract][Full Text] [Related]
19. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect.
Cao H; Chen ZX; Wang K; Ning MM; Zou QA; Feng Y; Ye YL; Leng Y; Shen JH
Sci Rep; 2016 Jun; 6():28676. PubMed ID: 27339735
[TBL] [Abstract][Full Text] [Related]
20. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
